Literature DB >> 16438763

A randomized, prospective double-blind comparison of the efficacy of generic propofol (sulphite additive) with diprivan.

A J Olufolabi1, T J Gan, H J Lacassie, W D White, A S Habib.   

Abstract

BACKGROUND AND
OBJECTIVE: We compared the dose requirement and side effect profile of total intravenous anaesthesia using Diprivan to generic propofol at a specific anaesthetic target level utilizing the bispectral index monitor to determine efficacy differences between the two products.
METHODS: Sixty women undergoing abdominal hysterectomy were induced with propofol 2 mg kg-1 and maintained with infusion (20-200 microg kg-1 min-1) adjusted to maintain a bispectral index of 50-65. Plasma propofol concentration was measured at 1 and 2 h post induction in 25 patients.
RESULTS: Mean (SD) drug doses adjusted for weight and time were similar in the Diprivan and generic propofol groups: 90 (30) microg kg-1 min-1 vs. 90 (20) microg kg-1 min-1 respectively. Mean (SD) plasma propofol levels at 1 and 2 h were also similar (3.0 (1.0) microg mL-1 vs. 3.6 (1.4) microg mL-1, P = 0.2 and 3.0 (1.9) microg mL-1 vs. 3.4 (1.6) microg mL-1, P = 0.58).
CONCLUSIONS: Diprivan and generic propofol have similar efficacy at a specified, bispectral index-defined, depth of anaesthesia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16438763     DOI: 10.1017/S0265021505001961

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  1 in total

1.  Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation.

Authors:  Nobuaki Ochi; Hiromichi Yamane; Katsuyuki Hotta; Hiromi Fujii; Hideko Isozaki; Yoshihiro Honda; Tomoko Yamagishi; Toshio Kubo; Mitsune Tanimoto; Katsuyuki Kiura; Nagio Takigawa
Journal:  Drug Des Devel Ther       Date:  2014-12-03       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.